Department of Pediatric Gastroenterology, Faculty of Medicine, Gaziantep University, Şehitkamil, 27310, Gaziantep, Turkey.
Department of Pediatric Gastroenterology, Antalya Education and Research Hospital, Kazım Karabekir St, 07100, Antalya, Turkey.
Probiotics Antimicrob Proteins. 2020 Mar;12(1):138-143. doi: 10.1007/s12602-019-9516-1.
This investigation has been performed to show the efficacy of Lactobacillus rhamnosus GG (LGG) together with milk-free diet in patients with cow's milk protein allergy (CMPA). This multicentre prospective investigation has been performed in 0-12 months of age children diagnosed as CMPA clinically and biochemically. Patients have been randomly divided in to two groups. İnfants in probiotic group were received with cow's milk protein free diet and per oral (p.o.) daily 1X10 CFU LGG and in placebo group with milk-free diet and placebo. Mothers of all breast-fed patients have been put on milk-free diet and all patients fed with formula, offered to extensively hydrolysed formula. Symptoms like diarrhoea, vomiting, mucousy or bloody stool, abdominal pain or distension, constipation, dermatitis and restiveness were recorded at the beginning and weekly during the receiving dietary by the investigator. One-hundred infants diagnosed CMPA were included in this double-blind placebo controlled study. Forty-eight infants placed in probiotic group and 52 in placebo group. After 4 weeks of receiving dietary, infants in probiotic group have showed statistically significant improvement in symptoms of bloody stool, diarrhoea, restiveness and abdominal distension (p ≤ 0.001). Whilst statistically significant improvement was also observed in symptoms of mucousy stool (p = 0.038) and vomiting (p = 0.034), no significant improvement were observed in abdominal pain (p = 0.325), constipation (p = 0.917) and dermatitis (p = 0.071). In this study we observed significant improvement in symptoms of infants diagnosed CMPA receiving dietary LGG with cow's milk-free diet.
本研究旨在探讨鼠李糖乳杆菌 GG(LGG)联合无牛奶饮食在牛乳蛋白过敏(CMPA)患儿中的疗效。本多中心前瞻性研究纳入了 0-12 月龄临床和生化诊断为 CMPA 的患儿。患儿随机分为两组。益生菌组接受无牛奶饮食和口服(p.o.)每日 1X10 CFU LGG,安慰剂组接受无牛奶饮食和安慰剂。所有母乳喂养患儿的母亲均接受无牛奶饮食,所有配方奶喂养患儿均提供深度水解配方奶。研究者在开始和每周记录接受饮食期间患儿的腹泻、呕吐、黏液或血便、腹痛或腹胀、便秘、皮疹和烦躁等症状。本双盲安慰剂对照研究纳入了 100 例诊断为 CMPA 的患儿。其中 48 例患儿纳入益生菌组,52 例患儿纳入安慰剂组。接受饮食 4 周后,益生菌组患儿便血、腹泻、烦躁和腹胀症状明显改善(p≤0.001)。黏液便(p=0.038)和呕吐(p=0.034)症状也有统计学显著改善,而腹痛(p=0.325)、便秘(p=0.917)和皮疹(p=0.071)无显著改善。本研究观察到接受无牛奶饮食和 LGG 的 CMPA 患儿症状明显改善。